Antineuronal Nuclear Antibody-Type 1 (ANNA-1) Titer, Serum
Use
The test is used for the diagnosis of paraneoplastic autoimmune neuropathies, encephalomyeloradiculopathies, related neurologic disorders, and intestinal pseudo-obstruction/dysmotility associated with small-cell lung carcinoma. It reports an end titer result from serum specimens. ANNA-1 antibody is a valuable marker of paraneoplastic intestinal dysmotilities associated with SCLC. It can help identify patients with small-cell lung carcinoma that may not be detectable with other cancers.
Special Instructions
Only orderable as a reflex test if the indirect immunofluorescence pattern suggests ANNA-1. If positive, the test is performed at an additional charge.
Limitations
ANNA-1 should not be used as a general screening test for lung carcinoma. It is rarely found in adult patients without asbestos exposure or tobacco history. False negatives can occur in cases where imaging fails to reveal existing small-cell lung carcinoma. ANNA-1 is only one of several neuronal antibodies associated with neurologic autoimmunity related to SCLC.
New York Approved
Methodology
Immunoassay (Indirect Immunofluorescence Assay (IFA))
Biomarkers
LOINC Codes
- 94342-3
- 94342-3
Result Turnaround Time
6-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
Not provided
Minimum Volume
0.6 mL
Storage Instructions
Refrigerated (preferred): 28 days; Ambient: 72 hours; Frozen: 28 days
Causes for Rejection
Gross hemolysis, Gross lipemia, Gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |